ReviewChemical & biomedical imaging2026
Recent Advances in Near-Infrared Probes for Monitoring Drug Treatment Responses: Toward Efficacy Evaluation and High-Throughput Screening.
Review in Chemical & biomedical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accurate drug efficacy evaluation and efficient potential drug screening are cornerstones of translational pharmacology, as they can directly underpin the optimization of therapeutic regimens, acceleration of drug development pipelines, and improvement of patient clinical outcomes. However, conventional analytical approaches for these tasks often suffer from inherent limitations, including invasiveness, low sensitivity to subtle molecular changes, inability to achieve real-time in vivo monitoring of therapeutic dynamics, and poor compatibility with physiologically relevant disease models. In response to these unmet needs, near-infrared (NIR) fluorescent probes have emerged as transformative tools, leveraging a suite of unique advantages, such as noninvasiveness, ultrahigh sensitivity, excellent target specificity, operational simplicity, deep tissue penetration, and cost-effectiveness, to enable precise, spatiotemporal tracking of drug actions in both preclinical and early clinical settings. This review provides a comprehensive, up-to-date overview of recent advances in the rational design and translational applications of NIR probes for drug efficacy assessment and high-throughput screening (HTS). Specifically, NIR probes can systematically detect drug-induced biochemical and microenvironmental alterations and, when are integrated into automated HTS platforms, significantly enhancing screening sensitivity, throughput, and physiological relevance. Finally, we delineate key challenges impeding the widespread clinical translation of NIR probe technology and outline future research directions. Progress in therapeutic areas holds profound potential to refine personalized drug treatment strategies, accelerate late-stage clinical trial validation, and drive paradigm-shifting innovations across the global pharmaceutical industry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.